Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

. 2018 Nov 29;2018:8693297. doi: 10.1155/2018/8693297

(b) UP2 level in the urine in BC patients and control group

Groups	UP2			p-value
	in urine [ng/mg cr.]			p-value
	Me	Mean	SD	in urine
BC	0.24	0.50	0.58	p≤0.001 BC vs C
C	0.07	0.08	0.04	p≤0.001 BC vs C

NMIBC	0.26	0.54	0.64	p=0.939 NMIBC vs MIBC
NMIBC	0.26	0.54	0.64	p≤0.001 NMIBC vs C
MIBC	0.24	0.38	0.32	p≤0.001 NMIBC vs C
MIBC	0.24	0.38	0.32	MIBC vs C p≤0.001

LG	0.25	0.55	0.66	p=0.846 LG vs HG
LG	0.25	0.55	0.66	p≤0.001 LG vs C
HG	0.26	0.45	0.47	p≤0.001 LG vs C
HG	0.26	0.45	0.47	p≤0.001 HG vs C

M	0.24	0.50	0.62	p=0.386 M vs W
W	0.56	0.49	0.31	p=0.386 M vs W

Non-smoking BC	0.64	0.85	0.90	p=0.640 non-smoking BC vs smoking BC
Smoking BC	0,24	0.43	0.46	p=0.640 non-smoking BC vs smoking BC

UP2: uroplakin 2; BC: patients group; C: control group; NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; M: men; W: women; SD: standard deviation; p: statistically significant difference; Me: median.